Kris Vulgan

FieldAI is the general-purpose brain making robots autonomous in complex, risky, real-world environments. We combine data-driven and physics-based methods to create the Field Foundation Model (FFM), the first risk-aware, physics-first foundation model for general-purpose robots across any robot type. The FFM works through a virtuous data flywheel that receives input, assesses uncertainty, establishes risk, and takes action based on that risk. Each deployment increases reliability and continuously enhances the capabilities of the global fleet, all without pre-trained data, GPS, maps, or pre-programmed routes. Our mission is to deploy autonomous robots at scale in any unstructured environment.

Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. Haima Therapeutics and Case Western Reserve University entered into an option to license agreement in April of 2018. Haima Therapeutics is located at the BioEnterprise incubator centrally located in the University Circle area near Case Western Reserve University, University Hospitals, and the Cleveland Clinic.

HOPO Therapeutics is a privately-held, clinical-stage pharmaceutical company developing treatments for heavy metal poisoning and pioneering novel methods for directed radioisotope delivery. Leveraging world-class expertise in the chemistry and biochemistry of heavy metals and technology licensed from Lawrence Berkeley National Laboratory, HOPO’s mission is to safeguard all people throughout the world from the harmful effects of heavy metal contamination while utilizing the power of metals in medicine to cure disease and improve lives.

Fig leads Security Operations Resilience – keeping detection and response working through constant change. Fig finds and fixes broken security flows across your entire SecOps stack and lets you quickly simulate and deploy planned changes. With Fig, change powers the SOC instead of breaking it.

KaloCyte, Inc., a preclinical biotech that has developed an artificial RBC substitute for use as a lifeline when blood is not available. We are located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark, and were selected as a BLUE KNIGHT™ Company. KaloCyte offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated preclinical safety and efficacy for ErythroMer, a shelf-stable, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $17M in federal awards and $5M investor funding. ErythroMer is a first-in-class, bio-inspired nanoparticle-encapsulated human hemoglobin, which mimics the vital oxygen-carrying functionality of RBCs and can be freeze-dried for long-term storage. Erythromer’s synthetic outer membrane, small size and surface area allow for physiologically realistic gas exchange. The synthetic polymer shell is “immune-silent”, inert and carries no blood antigens, eliminating the need to type and cross-match as with stored blood. ErythroMer can be freeze-dried or “lyophilized”, for a much longer shelf life than stored blood. It is covered by issued U.S. patents that specify composition of matter, method of preparation, and use as an oxygen carrier.

Seemplicity revolutionizes vulnerability and exposure management with its AI-powered Remediation Operations (RemOps) platform. By automating and streamlining remediation processes, Seemplicity consolidates findings, accelerates risk reduction, and delivers tailored remediation plans for security, IT, and DevOps teams. Trusted by Fortune 500 companies, the platform enables organizations to enhance operational resilience and build scalable security programs.

Vendict is redefining third-party risk management with advanced AI technology and GRC expertise. Vendict transforms previously slow, fragmented, and costly processes into fast, comprehensive, and affordable vendor risk reduction at scale across the extended enterprise From security questionnaires and audit prep to third-party risk and trust center workflows, Vendict eliminates manual grunt work and delivers source-backed answers you can rely on. Join the multi-billion-dollar companies and high-growth startups already using Vendict to move faster, reduce risk, and build trust with every response.

Morphoceuticals is a new biotech company creating the first map of the druggable bioelectrome. By using multi-omics, bioelectric profiling and AI, we aim to exploit the electrical network controlling tissue repair and organ regeneration that exists throughout our bodies.

Illuminating Protein Post Transational Modifications to Reveal Function!

Aperture Therapeutics is a biotechnology company developing a new class of therapeutics to treat injury- and age-induced neurodegeneration. The companys innovative platform leverages insight into disease resilience from large genomic and clinical data with streamlined drug discovery platform that generates drugs mimicking the effects of protective human gene variants.

Open-source inference server and production cluster for embeddings, reranking, and extraction. Cut API costs by 50x, boost quality with 85+ SOTA models, and keep your data in your own cloud.

BlakBear tells you how fresh your food is. We replace shelf-life on fresh food with a sensor that actually knows. Founded by scientists from Imperial College, we sell new sensors and a freshness API, to improve quality control, add shelf-life and cut food waste from producer to consumer.

Beacon is the security data management platform that helps modern security teams escape the tradeoff between coverage, context, and cost. With Beacon, you can seamlessly collect, reduce, enrich, and route your security data – so analysts and AI agents have the context and visibility to focus on security, not data wrangling. The result: cleaner data, faster investigations, and smarter security at scale.

Howdy fearless cybersecurity explorer! 🤠​ Lasso is the AI Security Platform built for the agentic era. By connecting discovery, AI risk management, automated red teaming, and runtime protection in a single continuous loop, Lasso ensures every agentic application behaves within its intended scope, at every stage of its lifecycle. For more information visit www.lasso.security.

Meet Ninja, your AI Agent for unlimited productivity. Assign Ninja tasks across research, writing, file analysis, coding, image generation, scheduling, and more.

FieldAI is the general-purpose brain making robots autonomous in complex, risky, real-world environments. We combine data-driven and physics-based methods to create the Field Foundation Model (FFM), the first risk-aware, physics-first foundation model for general-purpose robots across any robot type. The FFM works through a virtuous data flywheel that receives input, assesses uncertainty, establishes risk, and takes action based on that risk. Each deployment increases reliability and continuously enhances the capabilities of the global fleet, all without pre-trained data, GPS, maps, or pre-programmed routes. Our mission is to deploy autonomous robots at scale in any unstructured environment.

Haima Therapeutics is a pre-clinical stage biotechnology company focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. We have developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. Haima Therapeutics and Case Western Reserve University entered into an option to license agreement in April of 2018. Haima Therapeutics is located at the BioEnterprise incubator centrally located in the University Circle area near Case Western Reserve University, University Hospitals, and the Cleveland Clinic.

HOPO Therapeutics is a privately-held, clinical-stage pharmaceutical company developing treatments for heavy metal poisoning and pioneering novel methods for directed radioisotope delivery. Leveraging world-class expertise in the chemistry and biochemistry of heavy metals and technology licensed from Lawrence Berkeley National Laboratory, HOPO’s mission is to safeguard all people throughout the world from the harmful effects of heavy metal contamination while utilizing the power of metals in medicine to cure disease and improve lives.

Fig leads Security Operations Resilience – keeping detection and response working through constant change. Fig finds and fixes broken security flows across your entire SecOps stack and lets you quickly simulate and deploy planned changes. With Fig, change powers the SOC instead of breaking it.

KaloCyte, Inc., a preclinical biotech that has developed an artificial RBC substitute for use as a lifeline when blood is not available. We are located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark, and were selected as a BLUE KNIGHT™ Company. KaloCyte offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated preclinical safety and efficacy for ErythroMer, a shelf-stable, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $17M in federal awards and $5M investor funding. ErythroMer is a first-in-class, bio-inspired nanoparticle-encapsulated human hemoglobin, which mimics the vital oxygen-carrying functionality of RBCs and can be freeze-dried for long-term storage. Erythromer’s synthetic outer membrane, small size and surface area allow for physiologically realistic gas exchange. The synthetic polymer shell is “immune-silent”, inert and carries no blood antigens, eliminating the need to type and cross-match as with stored blood. ErythroMer can be freeze-dried or “lyophilized”, for a much longer shelf life than stored blood. It is covered by issued U.S. patents that specify composition of matter, method of preparation, and use as an oxygen carrier.